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Background: We investigated the association between supplemental folic acid in pregnancy and childhood cancer in a nation-
wide study of 687 406 live births in Norway, 1999–2010, and 799 children diagnosed later with cancer.
Methods: Adjusted hazard ratios (HRs) compared cancer risk in children by approximated periconceptional folic acid levels (folic
acid tablets and multivitamins (0.6 mg), only folic acid (0.4 mg), only multivitamins (0.2 mg)) and cancer risk in unexposed.
Results: Any folic acid levels were not associated with leukemia (e.g., high-level folic acid HR 1.25; 95% CI 0.89–1.76, PTrend 0.20),
lymphoma (HR 0.96; 95% CI 0.42–2.21, PTrend 0.51), central nervous system tumours (HR 0.68; 95% CI 0.42–1.10, PTrend 0.32),
neuroblastoma (HR 1.05; 95% CI 0.53–2.06, PTrend 0.85), Wilms’ tumour (HR 1.16; 95% CI 0.52–2.58, PTrend 0.76), or soft-tissue
tumours (HR 0.77; 95% CI 0.34–1.75, PTrend 0.90).
Conclusions: Folic acid supplementation was not associated with risk of major childhood cancers.
Health authorities in many countries recommend women planning
pregnancy to take folic acid before and during pregnancy to reduce
offspring risk of neural tube defects (SACN, 2006). A large number
of countries also fortify flour with folic acid (CDC, 2008).
Mandatory food fortification with folic acid is debated in some
countries because of the suggested cancer risk in adults (Kim, 2004;
Mason et al, 2007; Smith et al, 2008). However, in case–control
studies on children, cancer risks (leukemia, brain tumours) were
reduced if the mother had been exposed to perigestational
maternal folic acid supplementation (Thompson et al, 2001;
Milne et al, 2010; Milne et al, 2012; Metayer et al, 2014). And, in
ecological studies from Canada and the United States of America,
the childhood cancer incidence (Wilms’ tumour, primitive
neuroectodermal tumours, neuroblastoma) has been reduced
after mandatory folic acid flour fortification (French et al, 2003;
Grupp et al, 2011; Linabery et al, 2012).
The aim of our study was to investigate the association between
maternal intake of folic acid supplementation in pregnancy and
offspring risk of childhood cancer in a nation-wide cohort study in
Norway.
MATERIALS AND METHODS
Data sources. The unique personal identification number
assigned to all Norwegian residents enabled linkage of information
between the Medical Birth Registry of Norway (MBRN) (Irgens,
2000), the Cancer Registry of Norway (CRN) (Larsen et al, 2009),
and the Norwegian National Education Database that holds
information on all individuals’ education (Kinge et al, 2015).
Folic acid and multivitamin supplementation exposure. Folic
acid and multivitamin supplementation use has been registered in
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the MBRN since December 1998. The registration form uses check
boxes with the items ‘folic acid before pregnancy’, ‘folic acid during
pregnancy’, ‘multivitamins before pregnancy’, and ‘multivitamins
during pregnancy’. During the study period, the folic acid content
was 0.4 mg in folic acid supplements and approximately 0.2 mg in
multivitamin supplements. Children were defined as exposed to
folic acid if their mothers used folic acid supplements and/or
multivitamins before and/or during pregnancy. Maternal folic acid
intake was categorised by increasing folic acid content; no
supplement use (0 mg), only multivitamins (approximately
0.2 mg), only folic acid supplements (0.4 mg), or intake of both
folic acid supplements and multivitamins (approximately 0.6 mg).
Childhood cancer. Childhood cancer cases were identified through
linkage with CRN. For each child, the first cancer diagnosis was
used. The childhood cancers were categorised according to the
International Classification of Childhood Cancer, version 3, which is
based on ICD-O-3 (Steliarova-Foucher et al, 2005).
Study cohort. The study cohort consisted of all live births in
Norway, 1 January 1999 through 31 December 2010 (excluding
children with mothers with a prebirth cancer diagnosis (3371)),
with follow-up until a cancer diagnosis, emigration, death, or 31
December 2010.
Statistical analysis. Risk of childhood cancers in children exposed
to maternal folic acid and/or multivitamin supplements was
compared with cancer risk in unexposed children and estimated
with hazard ratios (HRs) using Cox proportional hazards
regression models with time since birth as the time variable,
adjusting for a priori selected covariates associated with maternal
folic acid use and childhood cancer risk; that is, birth order (1, 2,
X3), maternal smoking (never, sometimes, p10 cigarettes daily,
410 cigarettes daily, daily smoking of unknown amount),
maternal and paternal age (o25, 25–34, X35 years), and maternal
and paternal education (compulsory, intermediate, tertiary).
P-values for linear trend were calculated for folic acid exposure
levels (0 mg, 0.2 mg, 0.4 mg, 0.6 mg). Statistical analyses were
performed in STATA version 14 (STATA, 2015).
Ethics. The Regional Committee for Medical and Health Research
Ethics of Western Norway approved the study.
RESULTS
Among 687 406 children included in the study, 799 developed
cancer. The mean follow-up time was 6 years (range 0.04–12
years), constituting 4 052 679 person-years (Table 1). Among all
births, 4% were multiple births, and 2% were born after assisted
reproductive technology. Mean maternal age at childbirth was 29
years (range 13–55 years). The proportion of children exposed to
perigestational supplementation increased in the study period,
1999–2010; intake of folic acid changed from 18% to 69% and
multivitamins from 19% to 42%.
About 67% of all cancers were diagnosed within the first 3 years
of life (Table 2). Leukemia and central nervous system (CNS)
tumours accounted for 57% of the cases. We performed analyses
for the six most frequent childhood cancer types (leukemia,
lymphoma, CNS tumours, neuroblastoma, Wilms’ tumour, soft
tissue tumours) (Table 3). There was no change in childhood
leukemia risk by maternal use of multivitamins only (HR 1.23; 95%
CI 0.75–2.01), folic acid use only (HR 1.13; 95% CI 0.79–1.63), or
combined folic acid and multivitamin use (HR 1.25; 95%
CI 0.89–1.76), as compared with no supplement use (PTrend 0.20).
Similarly, there were no associations between CNS tumours and
different levels of maternal folic acid intake; multivitamins only
(HR 1.08; 95% CI 0.60–1.94), folic acid use only (HR 1.18; 95%
CI 0.78–1.78), or combined folic acid and multivitamin use
(HR 0.68; 95% CI 0.42–1.10), as compared with no supplement use
(PTrend 0.32). The HRs of the other frequent childhood cancer
types (lymphoma, neuroblastoma, Wilms’ tumour, soft tissue
tumours) did not change for different levels of folic acid exposure.
Adding birth year to adjustment models showed no substantial
Table 1. Characteristics of the study population of 687 406






Children 687 406 4 052 679 100 799
Sex
Boys 352 604 2 077 322 51 423
Girls 334 802 1 975 357 49 376
Gestational age (weeks)
o37 46 682 271 770 7 60
37–41 587 197 3 447 416 85 670
X42 48 830 307 613 8 62
Missing 4697 25 881 1 7
Birth weight (g)
o2500 33 804 191 809 5 39
2500–3999 516 075 3 008 163 74 587
X4000 136 760 847 264 21 173
Missing 767 5443 0 0
Birth order
1 284 468 1 651 442 41 339
2 244 834 1 446 964 36 281
X3 158 104 954 274 24 179
Maternal age at child birth, years
o25 117 065 697 604 17 133
25–34 452 481 2 709 049 67 539
X35 117 860 646 026 16 127
Paternal age at child birth, years
o25 52 776 312 202 8 65
25–34 396 496 2 406 027 59 468
X35 231 836 1 307 428 32 257
Missing 6298 27 023 1 9
Maternal educationa
Compulsory 128 452 782 418 19 148
Intermediate 232 745 1 475 123 36 288
Tertiary 299 871 1 662 622 41 340
Missing 26 338 132 516 3 23
Paternal educationa
Compulsory 129 537 779 208 19 142
Intermediate 301 918 1 842 424 45 373
Tertiary 227 910 1 297 762 32 251
Missing 28 041 133 286 3 33
Maternal smoking
Did not smoke 459 617 2 678 139 66 529
Smoked
sometimes
17 222 106 380 3 15
Smoked p10
cigarettes daily
69 270 455 935 11 103
Smoked 410
cigarettes daily
25 210 144 005 4 30
Smoked daily,
unknown amount
5331 33 502 1 4
Missing 110 756 634 718 16 118
Maternal supplementationb
No use 325 706 2 307 683 57 424
Multivitamins only 46 598 309 597 8 61
Folic acid only 145 856 675 461 17 154
Folic acid and
multivitamin use
169 246 759 938 19 160
aCompulsory education length was 9 years until 1996 and 10 years from 1997 onwards.
bMaternal supplement intake before and/or during pregnancy, categorised by folic acid
content: No use; multivitamins (approximately 0.2 mg); folic acid supplements (0.4 mg); and
folic acid and multivitamins (approximately 0.6 mg).
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changes in the risk estimates for neither cancer types. And
excluding 867 children with Down syndrome from the analyses did
not change the HR estimates for specific cancers.
DISCUSSION
In a nation-wide cohort study of all live births, estimated maternal
intakes of multivitamins, folic acid, or combined intake of these
supplements were not associated with childhood cancer.
Our results of no association between periconceptional folic acid
supplementation and major childhood cancers are in discordance
with case–control studies showing inverse associations between
self-reported folic acid use and acute lymphoblastic leukemia
(ALL) (Thompson et al, 2001; Milne et al, 2010; Metayer et al,
2014) and CNS tumours (Milne et al, 2012).
A recent large international collaborating study, including
47000 children with acute leukemia and 11 000 controls, found
reduced risks of ALL and acute myeloid leukemia (AML) after
maternal intake of folic acid supplements. And these reduced risks
of ALL and AML did not vary by timing of the supplementation
exposure (preconception, pregnancy, or pregnancy trimester)
(Metayer et al, 2014). However, an Australian study found weak
evidence of a reduced risk of ALL from folate supplementation
before pregnancy, but no reduced risk from use during pregnancy
(Milne et al, 2010). Also, another Australian study reported on an
inverse association of childhood brain tumours and folic
acid supplementation before and possibly also during pregnancy
(Milne et al, 2012). In our study, a further stratification of the
exposure data into preconceptional use and use during pregnancy
was not feasable due to the limited statistical power of the analyses.
The strengths of our study include using comprehensive data
from population-based registries covering the entire Norwegian
population. To our knowledge, Norway is the only country where
individual-level information on periconceptional folic acid and
multivitamin intake has been collected for the entire birth
population since 1999. All incident cancer cases have been
reported to the Cancer Registry of Norway since 1952 (Larsen
et al, 2009). And information on supplement use was collected
before cancer diagnosis precluding recall bias.
Table 2. Children with first-time childhood cancer (n¼799)
by age at diagnosis, year of diagnosis, and major cancer
types (ICCC-3), identified among 687 406 livebirths, Norway,
1999–2010
Cancer cases %















Acute myeloid leukemias 45
II Lymphomas and reticuloendothelial
neoplasms
42 5





Intracranial and intraspinal embryonal
tumours
50
IV Neuroblastoma and other peripheral nervous
cell tumours
72 9
Neuroblastoma and ganglioneuroblastoma 71
VI Renal tumours 53 7
Wilms’ tumour 52
IX Soft tissue and other extraosseous sarcomas 64 8
Rhabdomyosarcoma 24
Other specified soft tissue sarcomas 28
Other cancers 115 14
Total 799 100
Abbreviations: CNS¼ central nervous system; ICCC-3¼ International Classification of
Childhood Cancer, third edition (Steliarova-Foucher et al, 2005).
Table 3. Hazard ratios (HRs) with 95% confidence intervals (95% CI) of childhood cancer by perigestational supplementation of
folic acid and/or multivitamins, among 687 406 children, Norway, 1999–2010
Cancer types Supplementsa Cancer cases HRb 95% CI PTrend
All cancers No supplements 424 1.00 Reference
Multivitamins only 61 1.05 0.78–1.42
Folic acid only 154 1.13 0.92–1.38
Folic acid and multivitamins 160 1.02 0.83–1.25 0.60
I Leukemias, myeloproliferative diseases, and myelodysplastic diseases
No supplements 135 1.00 Reference
Multivitamins only 21 1.23 0.75–2.01
Folic acid only 50 1.13 0.79–1.63
Folic acid and multivitamins 62 1.25 0.89–1.76 0.20
(a) Lymphoid leukemia
No supplements 100 1.00 Reference
Multivitamins only 16 1.30 0.75–2.27
Folic acid only 42 1.30 0.87–1.95
Folic acid and multivitamins 50 1.31 0.89–1.94 0.12
(b) Acute myeloid leukemia
No supplements 28 1.00 Reference
Multivitamins only 3 0.97 0.29–3.27
Folic acid only 5 0.59 0.22–1.60
Folic acid and multivitamins 9 0.96 0.43–2.17 0.67
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The study had some limitations. Even though our cohort was large,
the numbers of several childhood cancer types were relatively low,
which may limit the statistical power of our findings. The follow-up
time of study participants were on average 6 years, and our results
could only be generalised to younger children. Maternal folic acid
intake could have been misclassified; in the beginning of the study
period, folic acid users were under-reported to the MBRN (Nilsen
et al, 2009). A possible misclassification of folic acid dose
(independent of cancer risk) would bias risk estimates towards the
null value and, in theory, could have concealed an association between
folic acid intake and childhood cancer risk. Information on maternal
smoking was missing for 16% of the births; however, HR estimates
adjusting for maternal smoking were similar to HRs without smoking
adjustments. Although we did not have information on dietary folate,
residual confounding by dietary folate is less likely. In pregnant
women, maternal plasma levels of serum folate is strongly related to
intake of folic acid supplements (Bjorke-Monsen et al, 2013). And in
other studies of maternal intake of folic acid supplements and
offspring outcomes (oral clefts, autism), adjustment for dietary folate
did not change overall risk estimates (Wilcox et al, 2007; Suren et al,
2013). We could not adjust for mother’s weight and height, physical
activity, diet, use of alcohol, or use of contraceptive pills, as these
covariates were not available in the MBRN.
In conclusion, we found no association between maternal
supplemental folic acid intake before and/or during pregnancy and
risk of leukemia, lymphomas, CNS tumours, neuroblastoma,
Wilms’ tumour, or soft tissue tumours among younger children.
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Table 3. ( Continued )
Cancer types Supplementsa Cancer cases HRb 95% CI PTrend
II Lymphomas and reticuloendothelial neoplasms
No supplements 25 1.00 Reference
Multivitamins only 3 0.55 0.13–2.33
Folic acid only 5 0.40 0.12–1.34
Folic acid and multivitamins 9 0.96 0.42–2.21 0.51
III CNS and miscellaneous intracranial and intraspinal neoplasms
No supplements 107 1.00 Reference
Multivitamins only 14 1.08 0.60–1.94
Folic acid only 37 1.18 0.78–1.78
Folic acid and multivitamins 27 0.68 0.42–1.10 0.32
(b) Astrocytoma
No supplements 44 1.00 Reference
Multivitamins only 8 1.57 0.72–3.40
Folic acid only 15 1.31 0.70–2.45
Folic acid and multivitamins 12 0.86 0.43–1.73 0.97
(c) Intracranial and intraspinal embryonal tumours
No supplements 28 1.00 Reference
Multivitamins only 2 0.61 0.14–2.59
Folic acid only 12 1.28 0.60–2.76
Folic acid and multivitamins 8 0.69 0.27–1.74 0.69
IV Neuroblastoma and other peripheral nervous cell tumours
(a) Neuroblastoma and ganglioneuroblastoma
No supplements 37 1.00 Reference
Multivitamins only 5 0.99 0.35–2.82
Folic acid only 15 1.08 0.54–2.15
Folic acid and multivitamins 14 1.05 0.53–2.06 0.85
VI Renal tumours
(a) Wilms’ tumour
No supplements 28 1.00 Reference
Multivitamins only 5 1.60 0.60–4.25
Folic acid only 9 1.01 0.42–2.40
Folic acid and multivitamins 10 1.16 0.52–2.58 0.76
IX Soft tissue and other extraosseous sarcomas
No supplements 32 1.00 Reference
Multivitamins only 5 1.12 0.39–3.22
Folic acid only 18 1.72 0.90–3.29
Folic acid and multivitamins 9 0.77 0.34–1.75 0.90
Abbreviation: CNS¼ central nervous system.
aMaternal supplement intake before and/or during pregnancy, categorised by folic acid content: No use; multivitamins (approximately 0.2 mg); folic acid supplements (0.4 mg); and folic acid
and multivitamins (approximately 0.6 mg).
bHazard ratios (HR) with 95% confidence intervals (95% CI) adjusted for birth order (1, 2, X3), smoking (never, sometimes, p10 cigarettes daily, 410 cigarettes daily, daily smoking of unknown
amount), maternal and paternal age (o25, 25–34, X35 years), and maternal and paternal education (compulsory, intermediate, tertiary) comparing cancer risk in children exposed to
periconceptional folic acid (multivitamins, folic acid, folic acid and multivitamins) and cancer risk in children without perigestational folic acid exposure (reference).
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